177Lu-PSMA-617 as a new treatment option for therapy of metastatic castration resistant prostate cancer : a retrospective study
Latest Information Update: 18 May 2017
Price :
$35 *
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- 18 May 2017 New trial record